Thermo Fisher Scientific Inc. $TMO Holdings Lowered by Rockland Trust Co.

Rockland Trust Co. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 46.3% during the 3rd quarter, Holdings Channel reports. The fund owned 34,723 shares of the medical research company’s stock after selling 29,916 shares during the quarter. Rockland Trust Co.’s holdings in Thermo Fisher Scientific were worth $23,440,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of TMO. Violich Capital Management Inc. grew its stake in shares of Thermo Fisher Scientific by 21.4% during the 3rd quarter. Violich Capital Management Inc. now owns 1,335 shares of the medical research company’s stock worth $901,000 after purchasing an additional 235 shares during the period. Polaris Financial Partners purchased a new stake in Thermo Fisher Scientific during the third quarter worth $32,000. Global Wealth Strategies & Associates purchased a new position in Thermo Fisher Scientific in the third quarter valued at $271,000. Versant Capital Management Inc raised its position in shares of Thermo Fisher Scientific by 35.8% in the third quarter. Versant Capital Management Inc now owns 1,165 shares of the medical research company’s stock worth $786,000 after acquiring an additional 307 shares during the period. Finally, Burkett Financial Services LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth about $65,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $12.17 during mid-day trading on Monday, reaching $666.97. 640,221 shares of the stock traded hands, compared to its average volume of 2,243,463. The stock has a market capitalization of $246.61 billion, a PE ratio of 35.87, a PEG ratio of 2.74 and a beta of 0.87. The business has a 50-day moving average of $618.62 and a 200 day moving average of $535.16. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $683.63. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the previous year, the company posted $4.28 earnings per share. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. Wells Fargo & Company lowered Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research note on Wednesday, September 9th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. BMO Capital Markets downgraded Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Royal Bank Of Canada lifted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Finally, Barclays upped their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $628.78.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.